We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
-20.62%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$365M
AUM Growth
+$32.8M
Cap. Flow
+$141M
Cap. Flow %
38.7%
Top 10 Hldgs %
100%
Holding
9
New
2
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$82.4M
2
AKRO
Akero Therapeutics
AKRO
+$58.7M

Top Sells

Rank Stock Value
1
VANI icon
Vivani Medical
VANI
+$40

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.68B
$177M 48.6%
4,205,615
– –
ADVM
2
DELISTED
Adverum Biotechnologies
ADVM
$69.1M 18.94%
+706,823
New +$82.4M
AKRO
3
DELISTED
Akero Therapeutics
AKRO
$58M 15.91%
+2,736,572
New +$58.7M
VCYT icon
4
Veracyte
VCYT
$4.44B
$29.3M 8.04%
1,205,407
– –
GRTS
5
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$18.1M 4.95%
3,102,929
– –
OCUL icon
6
Ocular Therapeutix
OCUL
$1.85B
$11M 3.01%
2,215,384
– –
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
$805K 0.22%
543,753
– –
CLVS
8
DELISTED
Clovis Oncology, Inc.
CLVS
$648K 0.18%
101,855
– –
VANI icon
9
Vivani Medical
VANI
$113M
$559K 0.15%
187,204
-3
-0% -$40

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q1 2020 Portfolio in Review

As of Q1 2020, Versant Venture Management held 9 positions worth $365M, up 9.9% from $332M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management deployed $141M of net new capital in Q1 2020, opening 2 new positions. Its largest new stake was Adverum Biotechnologies: 706,823 shares worth $69.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Vivani Medical, an estimated $40 trimmed.

  • Versant Venture Management's largest Q1 2020 buy was Adverum Biotechnologies: 706,823 shares worth $69.1M.
  • Versant Venture Management's biggest Q1 2020 reduction was Vivani Medical, cutting an estimated $40.
  • Versant Venture Management's ten largest holdings make up 100% of its $365M portfolio in Q1 2020.
  • Versant Venture Management opened 2 new positions and closed 0 in Q1 2020.
  • Versant Venture Management's portfolio value rose 9.9% quarter-over-quarter to $365M.

Based on Versant Venture Management's 13F filing for Q1 2020, filed 28 Apr 2020.